Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients
Status:
Unknown status
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if the DNA vaccine CHRONVAC-C® intended for future
treatment of Hepatitis C infections is safe and tolerated when administered to HCV infected
individuals with a low viral load. In addition the capability of the vaccine to induce an
immune response and the effect on viral load will be studied. In order to increase the uptake
of the vaccine the intra muscular injection is combined with electroporation, meaning that a
brief electric field is applied to the injection site resulting in temporary pores in the
cell membranes that allows the vaccine to enter the cells.